🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Molecules of the Month - July 23 | drughunters.com/3KwRntK This month features big announcements from Biogen-Reata acquisition for their premier Friedreich’s ataxia drug, and BridgeBio positive Ph. III ATTR-CM treatment data. #chemistry #drugdiscovery #pharmaceutials

Really cool! I will for sure go and see it the next time I am close to #Donaukanal.

A fantastic conference in a stunning venue to celebrate a field-changing effort by the RESOLUTE - Research Empowerment on Solute Carriers consortium! We are thankful that several @Solgate team members could attend, presenting a poster&talk and introducing our work to the community.

Very happy to share this pre-print on pan-KARS degraders! Centre for Targeted Protein Degradation Boehringer Ingelheim collaboration. Thanks to the great team Johannes Popow, Will Farnaby, Christiane Kofink, Harald Weinstabl, Peter Ettmayer, Alessio Ciulli and many more colleagues biorxiv.org/content/10.110…

Exciting times to work in small-molecule drug discovery! So many new opportunities; incredible pace : cen.acs.org/pharmaceutical…

Treatment with a potent MDM2 antagonist in p53 wildtype liposarcoma induces p53 mutations, but interestingly this does not lead to acquired resistance to such compound. See our poster at CTOS today.

Brigimadlin: MDM2-p53 antagonist for #liposarcoma by Patrick Schöffski at #CTOS2023 Ph 1a/1b; n=145 ✅ Dose finding complete 💊 Oral q3w 😷 Low discontinuation due to toxicity 76/79 ddLPS evaluable -rx ongoing n=31 👏 median PFS 8.1m BRIGHTLINE-1 ph II/III RCT awaited #CTOSTweeTOS

Great to see applications of MDM2::p53 inhibitors beyond oncology and great to see this work published! antonio filareto Harald Weinstabl

I’m happy to share this new method to make substituted #indazoles which was recently published in OL J Org Chem/Org Lett. It is particularly useful if your molecule doesn’t like reductive conditions. Big thank you to the team at Boehringer Ingelheim. pubs.acs.org/doi/10.1021/ac…

Are you eager to combine protein-protein interaction data of transmembrane proteins with the knowledge from protein structures and genetic variants using artificial intelligence and machine learning? The GSF Lab is looking for a computational biologist. cemm.onlyfy.jobs/job/gyq10ma9

BI-0474 is a novel, covalent inhibitor of KRAS G12C, discovered by a Vanderbilt University, Boehringer Ingelheim collaboration by first optimizing weakly binding fragment hits. You can order it for free on opnMe: bit.ly/3QUJKRe

Congrats to our team Boehringer Ingelheim for publishing our latest research on targeting #MDM2 in MCT Molecular Cancer Therapeutics AACR Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules aacrjournals.org/mct/article/do…

Happy to share the collaborative work of Alessio Ciulli group and Boehringer Ingelheim Vienna on pan-KRAS degraders. It was great to work together with so many talented people to deliver ACBI3. Targeting cancer with small-molecule pan-KRAS degraders | Science science.org/doi/10.1126/sc…

Our collaborative research with Centre for Targeted Protein Degradation on a novel approach to target several KRAS mutants, a key protein involved in cancer growth, was just published in Science Magazine. Learn more: go.boehringer.com/science #Cancer #ResearchAndDevelopment #Oncology

The first of a series of four papers transforming SLC research. Congratulations to the RESOLUTE consortium!

Nice feature article in C&EN (Chemical & Engineering News) on our recent pan-KRAS degrader article. science.org/doi/10.1126/sc…

Do you want to know with which proteins an SLC membrane transporter socializes? Our RESOLUTE - Research Empowerment on Solute Carriers series of 4 manuscripts continues, and we are excited to share the so far most comprehensive interactome mapping of solute carriers biorxiv.org/content/10.110…

Clinically relevant anti-tumor activity of the MDM2 antagonist brigimadlin in advanced dediff. liposarcoma in first line in Phase II/III study Brightline-1: 22.3% objective responses and 86.5 % disease control rate, confirming earlier Phase 1 data. Schöffski et al., CTOS 2024

Superior activity of MDM2 antagonist brigimadlin in „locally advanced“ and „prior surgery“ subsets of patients with dedifferentiated liposarcoma in Brightline-1: a strong argument for a neoadjuvant or perioperative trial in relapsing retroperitoneal disease?